Lazard Asset Management
IPSC icon

Lazard Asset Management’s Century Therapeutics IPSC Stock Holding History

Lazard Asset Management’s Portfolio IPSC Stock Details IPSC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-62,947
Closed -$35K – 2066
2025
Q2 		$35K Buy
+62,947
New +$33.8K ﹤0.01% 2060
2023
Q3 		– Sell
-930
Closed -$2K – 2377
2023
Q2 		$2K Buy
930
+35
+4% +$113 ﹤0.01% 2230
2023
Q1 		$3K Buy
895
+168
+23% +$738 ﹤0.01% 2187
2022
Q4 		$3K Buy
+727
New +$6.86K ﹤0.01% 2270

Other funds holding IPSC

BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DCM
DAFNA Capital Management Los Angeles, California $440M AUM 109.12% 1-Year Est. Return
CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return
SP
Syncona Portfolio St Peter Port, Guernsey $25.7M AUM 13.32% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Lazard Asset Management's IPSC Position: Q3 2025 in Review

Lazard Asset Management sold out of Century Therapeutics (IPSC) in Q3 2025, closing a stake of 62,947 shares — an estimated $35K sold.

Lazard Asset Management first reported a position in IPSC in Q4 2022 and held it in 4 quarters. The position peaked at $35K in Q2 2025. 57 funds tracked by Wall St. Rank hold IPSC as of Q3 2025.

  • Lazard Asset Management reported no remaining Century Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Lazard Asset Management sold 62,947 Century Therapeutics shares in Q3 2025, an estimated $35K.
  • Lazard Asset Management first reported a position in Century Therapeutics in Q4 2022 and held it in 4 quarters.
  • Lazard Asset Management's Century Therapeutics position peaked at $35K in Q2 2025.
  • 57 funds tracked by Wall St. Rank held Century Therapeutics as of Q3 2025.

Based on Lazard Asset Management's 13F filing for Q3 2025, filed 14 Nov 2025.